
Dhruv S Kazi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6945982/publications.pdf

Version: 2024-02-01



ΠΗΡΙΙΝ S ΚΛΖΙ

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Thresholds for the cost–effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization, 2015, 93, 118-124. | 3.3 | 614 |
| 2 | Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2016, 316, 743. | 7.4 | 286 |
| 3 | Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224. | 1.6 | 147 |
| 4 | Cardiovascular Deaths During the COVID-19ÂPandemic in the United States. Journal of the American College of Cardiology, 2021, 77, 159-169. | 2.8 | 147 |
| 5 | Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA - Journal of the American Medical Association, 2017, 318, 748. | 7.4 | 130 |
| 6 | Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiology, 2019, 4, 1084. | 6.1 | 124 |
| 7 | Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1719-1726. | 2.7 | 117 |
| 8 | Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology, 2014, 64, 247-252. | 2.8 | 113 |
| 9 | Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. Global Heart, 2015, 10, 111. | 2.3 | 104 |
| 10 | Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ: British Medical Journal, 2018, 363, k5094. | 2.3 | 103 |
| 11 | Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiology, 2019, 4, 671. | 6.1 | 102 |
| 12 | Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2015, 65, 1411-1420. | 2.8 | 101 |
| 13 | PCSK9 Inhibitors. Journal of the American College of Cardiology, 2017, 70, 2677-2687. | 2.8 | 96 |
| 14 | Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. Annals of Internal Medicine, 2014, 160, 221-232. | 3.9 | 84 |
| 15 | Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation, 2017, 136, 1087-1098. | 1.6 | 79 |
| 16 | Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. JAMA Cardiology, 2020, 5, 899. | 6.1 | 79 |
| 17 | Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data. JAMA Network Open, 2018, 1, e185097. | 5.9 | 72 |
| 18 | Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. Circulation, 2021, 143, 2346-2354. | 1.6 | 70 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiology, 2021, 6, 1406. | 6.1 | 68 |
| 20 | Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. JAMA Internal Medicine, 2016, 176, 635. | 5.1 | 61 |
| 21 | Cost-Effectiveness of Alirocumab. Annals of Internal Medicine, 2019, 170, 221. | 3.9 | 57 |
| 22 | Statins for Primary Prevention of Cardiovascular Disease. Medical Clinics of North America, 2017, 101, 689-699. | 2.5 | 53 |
| 23 | Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501. | 5.9 | 49 |
| 24 | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels. JAMA Internal Medicine, 2016, 176, 107. | 5.1 | 41 |
| 25 | Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. JAMA Cardiology, 2019, 4, 828. | 6.1 | 40 |
| 26 | Angina and associated healthcare costs following percutaneous coronary intervention: A realâ€world analysis from a multiâ€payer database. Catheterization and Cardiovascular Interventions, 2016, 88, 1017-1024. | 1.7 | 36 |
| 27 | Cost-effectiveness of Low-density Lipoprotein Cholesterol Level–Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiology, 2019, 4, 969. | 6.1 | 30 |
| 28 | Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. The Lancet Global Health, 2019, 7, e1346-e1358. | 6.3 | 30 |
| 29 | Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open, 2019, 9, e027432. | 1.9 | 30 |
| 30 | PrEParing to End the HIV Epidemic — California's Route as a Road Map for the United States. New England Journal of Medicine, 2019, 381, 2489-2491. | 27.0 | 28 |
| 31 | Association of Homelessness with Hospital Readmissions—an Analysis of Three Large States. Journal of General Internal Medicine, 2020, 35, 2576-2583. | 2.6 | 28 |
| 32 | Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2249-2257. | 2.8 | 27 |
| 33 | Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. Annals of Internal Medicine, 2022, 175, 765-773. | 3.9 | 27 |
| 34 | Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. JAMA - Journal of the American Medical Association, 2020, 323, 1614. | 7.4 | 26 |
| 35 | Public health aspects of the world's largest mass gathering: The 2013 Kumbh Mela in Allahabad, India. Journal of Public Health Policy, 2016, 37, 411-427. | 2.0 | 25 |
| 36 | Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine, 2017, 177, 585. | 5.1 | 25 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. JAMA - Journal of the American Medical Association, 2021, 325, 445. | 7.4 | 24 |
| 38 | Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. Circulation, 2021, 143, 2384-2394. | 1.6 | 24 |
| 39 | Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model. Journal of General Internal Medicine, 2015, 30, 1147-1155. | 2.6 | 23 |
| 40 | Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. JAMA Internal Medicine, 2020, 180, 1696. | 5.1 | 23 |
| 41 | Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 203-213. | 1.6 | 23 |
| 42 | Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. Journal of the American College of Cardiology, 2021, 78, 1954-1964. | 2.8 | 23 |
| 43 | The Economics of Heart Failure. Heart Failure Clinics, 2013, 9, 93-106. | 2.1 | 22 |
| 44 | Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. JAMA Cardiology, 2017, 2, 1164. | 6.1 | 22 |
| 45 | Using Mobile Health Intervention to Improve Secondary Prevention of Coronary Heart Diseases in China: Mixed-Methods Feasibility Study. JMIR MHealth and UHealth, 2018, 6, e9. | 3.7 | 22 |
| 46 | Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10. | 4.9 | 22 |
| 47 | Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. Cardiology Clinics, 2008, 26, 1-14. | 2.2 | 20 |
| 48 | Using mobile technology to optimize disease surveillance and healthcare delivery at mass gatherings: a case study from India's Kumbh Mela. Journal of Public Health, 2016, 39, 616-624. | 1.8 | 19 |
| 49 | Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1777-1785. | 2.9 | 19 |
| 50 | Generalizability of Clinical Trials Supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. JAMA Internal Medicine, 2020, 180, 795. | 5.1 | 17 |
| 51 | Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women. Drug and Alcohol Dependence, 2020, 217, 108252. | 3.2 | 16 |
| 52 | Development of a mobile phone-based intervention to improve adherence to secondary prevention of coronary heart disease in China. Journal of Medical Engineering and Technology, 2016, 40, 372-382. | 1.4 | 15 |
| 53 | Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. New England Journal of Medicine, 2020, 382, 2354-2364. | 27.0 | 15 |
| 54 | Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS ONE, 2020, 15, e0222801. | 2.5 | 13 |

| # | Article | IF | CITATIONS |
|----|---|-----------------|-------------------|
| 55 | Characteristics of Populations Excluded From Clinical Trials Supporting Intensive Blood Pressure Control Guidelines. Journal of the American Heart Association, 2021, 10, e019707. | 3.7 | 13 |
| 56 | Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004–17. Health Affairs, 2021, 40, 289-296. | 5.2 | 12 |
| 57 | Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein) Tj ETQq1 1 0.784314 Quality and Outcomes, 2021, 14, e007521. | rgBT /Ον 2.2 | erlock 10 T 12 |
| 58 | Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008477. | 3.9 | 12 |
| 59 | Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Progress in Cardiovascular Diseases, 2019, 62, 406-413. | 3.1 | 10 |
| 60 | From Innovation to Implementation. Journal of the American College of Cardiology, 2014, 64, 2616-2618. | 2.8 | 9 |
| 61 | Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. Circulation, 2021, 143, 2406-2408. | 1.6 | 9 |
| 62 | Establishment of a cardiac telehealth program to support cardiovascular diagnosis and care in a remote, resource-poor setting in Uganda. PLoS ONE, 2021, 16, e0255918. | 2.5 | 9 |
| 63 | Cost-Effectiveness of Screening Ultrasound after a First, Febrile Urinary Tract Infection in Children Age 2-24ÂMonths. Journal of Pediatrics, 2020, 216, 73-81.e1. | 1.8 | 8 |
| 64 | Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1072-1078. | 4.9 | 8 |
| 65 | Potential impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, | 2.2 | 7 |
| 66 | Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults. Journal of the American Heart Association, 2022, 11, e025192. | 3.7 | 7 |
| 67 | Warfarin, Genes, and the (Health Care) Environment. JAMA Internal Medicine, 2014, 174, 1338. | 5.1 | 6 |
| 68 | Rising above the rhetoric: mobile applications and the delivery of cost-effective cardiovascular care in resource-limited settings. Future Cardiology, 2015, 11, 1-4. | 1.2 | 6 |
| 69 | Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 273-279. | 4.0 | 6 |
| 70 | The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. Current Cardiology Reports, 2021, 23, 163. | 2.9 | 6 |
| 71 | Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690. | 3.0 | 5 |
| 72 | Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiology, 2022, 7, 110. | 6.1 | 5 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Development and validation of an echocardiographic algorithm to predict long-term mitral and tricuspid regurgitation progression. European Heart Journal Cardiovascular Imaging, 2022, 23, 1606-1616. | 1.2 | 5 |
| 74 | A prospective cohort study examining exposure to incarceration and cardiovascular disease (Justice-Involved Individuals Cardiovascular Disease Epidemiology – JUSTICE study): a protocol paper. BMC Public Health, 2022, 22, 331. | 2.9 | 5 |
| 75 | Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. Heart, 2021, 107, 1267-1268. | 2.9 | 4 |
| 76 | A Delicate Balance. Journal of the American College of Cardiology, 2015, 65, 477-479. | 2.8 | 3 |
| 77 | Cost-effectiveness of PCSK9 Inhibitor Therapy—Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2152. | 7.4 | 3 |
| 78 | From Molecules to Markets. Circulation: Heart Failure, 2018, 11, e004815. | 3.9 | 3 |
| 79 | Who Is Rescuing Whom?. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005887. | 2.2 | 3 |
| 80 | Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice. JACC: Cardiovascular Interventions, 2021, 14, 2112-2123. | 2.9 | 3 |
| 81 | Infective endocarditis and antibiotic prophylaxis. Lancet, The, 2015, 386, 530. | 13.7 | 2 |
| 82 | Building the Economic Case for InvestmentÂin Cardiovascular Prevention. Journal of the American College of Cardiology, 2018, 71, 1090-1093. | 2.8 | 2 |
| 83 | Accurately Predicting Cardiovascular Risk—and Acting on It. Annals of Internal Medicine, 2020, 172, 61. | 3.9 | 2 |
| 84 | Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India. Indian Heart Journal, 2021, 73, 169-173. | 0.5 | 2 |
| 85 | Addressing the Last-Mile Problem in Blood Pressure Control—Scaling Up Community-Based Interventions. JAMA Health Forum, 2021, 2, e212022. | 2.2 | 2 |
| 86 | Evaluation of a Health Information Technology–Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. JMIR Research Protocols, 2020, 9, e13835. | 1.0 | 2 |
| 87 | Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121008443. | 2.2 | 2 |
| 88 | Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2021, 326, 2372. | 7.4 | 2 |
| 89 | Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy― Circulation, 2020, 142, e212-e213. | 1.6 | 1 |
| 90 | Prognosis of Claims―Versus Trialâ€Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal of the American Heart Association, 2021, 10, e018744. | 3.7 | 1 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Patterns of Recovery in Cardiovascular Care after the COVID-19 Pandemic Surge. American Journal of the Medical Sciences, 2021, , . | 1.1 | 1 |
| 92 | Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. Clinical Chemistry, 2021, 67, 1312-1317. | 3.2 | 1 |
| 93 | Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience. PLoS ONE, 2020, 15, e0244379. | 2.5 | 1 |
| 94 | The Value of Pharmacogenetic Testing—Reply. JAMA Internal Medicine, 2015, 175, 314. | 5.1 | 0 |
| 95 | 1788. Cost-Effectiveness of Penicillin Skin Testing Among Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. Open Forum Infectious Diseases, 2018, 5, S506-S507. | 0.9 | 0 |
| 96 | Prevalence and Risk Factors for Preprocedural Medication Errors in Patients With Atrial Fibrillation and Atrial Flutter. Cardiology Research, 2021, 12, 265-268. | 1.1 | 0 |